Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Andrology ; 3(1): 13-8, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25331158

ABSTRACT

Testicular germ cell tumors (TGCT), which comprise 98% of all testicular malignancies, are the most commonly occurring cancers among men between the ages of 15 and 44 years in the United States (US). A prior report from our group found that while TGCT incidence among all US men increased between 1973 and 2003, the rate of increase among black men was more pronounced starting in 1989-1993 than was the rate of increase among other men. In addition, TGCT incidence increased among Hispanic white men between 1992 and 2003. To determine whether these patterns have continued, in the current study, we examined temporal trends in incidence through 2011. Between 1992 and 2011, 21 271 TGCTs (12 419 seminomas; 8715 non-seminomas; 137 spermatocytic seminomas) were diagnosed among residents of the Surveillance, Epidemiology, and End Results 13 registry areas. The incidence of TGCT was highest among non-Hispanic white men (6.97 per 100 000 man-years) followed by American Indian/Alaska Native (AI/AN; 4.66), Hispanic white (4.11), Asian/Pacific Islander (A/PI; 1.95), and black (1.20) men. Non-Hispanic white men were more likely to present with smaller tumors (3.5 cm) and localized disease (72.6%) than were men of other races/ethnicities. Between 1992 and 2011, TGCT incidence increased significantly among Hispanic white [annual percent change (APC) = 2.94, p < 0.0001], black (APC = 1.67, p = 0.03), non-Hispanic white (APC = 1.23, p < 0.0001), and A/PI (APC = 1.04, p = 0.05) men. Incidence rates also increased, although not significantly, among AI/AN men (APC = 2.96, p = 0.06). The increases were greater for non-seminoma than seminoma. In summary, while non-Hispanic white men in the US continue to have the highest incidence of TGCT, they present at more favorable stages of disease and with smaller tumors than do other men. The increasing rates among non-white men, in conjunction with the larger proportion of non-localized stage disease, suggest an area where future research is warranted.


Subject(s)
Neoplasms, Germ Cell and Embryonal/epidemiology , Seminoma/epidemiology , Testicular Neoplasms/epidemiology , Adolescent , Adult , Humans , Incidence , Male , Neoplasm Staging , Neoplasms, Germ Cell and Embryonal/ethnology , Neoplasms, Germ Cell and Embryonal/pathology , Racial Groups , Risk Factors , SEER Program , Seminoma/ethnology , Seminoma/pathology , Testicular Neoplasms/ethnology , Testicular Neoplasms/pathology , Time Factors , Tumor Burden , United States/epidemiology , Young Adult
2.
Exp Mol Pathol ; 69(3): 242-7, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11115365

ABSTRACT

The inflammatory cytokine makeup of healing wounds helps delineate the phases of the repair process. As an example, during the lag phase (inflammatory phase) of repair, elevated levels of IL-8, a chemokine, participate in the activation and chemotaxis of neutrophils. During the normal proliferative and remodeling phases of repair, IL-8 levels are minimal. Healing burn wounds often have small, open, slow-to-heal areas, which have been shown to contain elevated levels of IL-8. Does a limited exposure of IL-8 to fibroblasts in vitro at the concentrations measured in these unhealed sites cause altered cell behavior? To study this possibility the fibroblast-populated collagen lattice (FPCL) model, an in vitro model of wound contraction, was used to investigate fibroblast response to IL-8. As previously reported, the chronic exposure of fibroblasts to IL-8 at 30 ng/ml within FPCLs significantly inhibited FPCL contraction. Fibroblasts in monolayer culture were incubated with IL-8 for 3 days. In the absence of IL-8, FPCLs were manufactured with these preexposed cells and it was found that FPCL contraction was inhibited. Fibroblasts retained their reduced capacity of reorganizing collagen fibrils when previously exposed to IL-8. Treating fibroblasts in monolayer with IL-8 for only 1 h prior to their incorporation into collagen lattices caused inhibition of FPCL contraction. The speculation is that in vivo open areas in reepithelialized healed burns are the consequence of the local population of fibroblasts having been exposed to elevated levels of IL-8. Such an earlier exposure triggers a memory in this population of fibroblasts that alters their capacity to lay down an extracellular matrix that optimizes the migration of epidermal cells.


Subject(s)
Collagen/drug effects , Fibroblasts/drug effects , Interleukin-8/pharmacology , Cells, Cultured , Collagen/metabolism , Dose-Response Relationship, Drug , Fibroblasts/cytology , Fibroblasts/metabolism , Humans , Microscopy, Phase-Contrast , Time Factors
3.
Arch Int Pharmacodyn Ther ; 318: 66-75, 1992.
Article in English | MEDLINE | ID: mdl-1463372

ABSTRACT

Cerebral ischemia was induced in rabbits by selective injection of 4 beta-phorbol-12 beta-myristate-13 alpha-acetate (PMA) into the left carotid artery. PMA provoked intravascular platelet and neutrophil aggregation. After PMA injection, a significant decrease in platelet and neutrophil counts was observed. Platelet and neutrophil emboli caused ischemia of the brain and brain barrier damage with accumulation of sodium fluorescein in the cerebrospinal fluid. Regional tissue analysis showed an ipsilateral alteration of the cerebral energy state and increased lactate levels. Pretreatment with the prostacyclin infusion completely blocked the alterations in both platelet and leukocytes counts and decreased the cerebral energy failure. Nimodipine administration decreased the changes in platelet and neutrophil counts and prevented the development of both brain barrier and cerebral energy failure. Nicergoline had no statistically significant beneficial effect on PMA-induced cerebrovascular injury.


Subject(s)
Cerebrovascular Disorders/drug therapy , Leukocytes/drug effects , Nicergoline/pharmacology , Nimodipine/pharmacology , Platelet Activation/drug effects , Animals , Blood-Brain Barrier/drug effects , Brain Chemistry/drug effects , Carotid Arteries , Cerebrovascular Disorders/blood , Cerebrovascular Disorders/chemically induced , Energy Metabolism/drug effects , Injections, Intra-Arterial , Leukocyte Count/drug effects , Nicergoline/administration & dosage , Nimodipine/administration & dosage , Platelet Count/drug effects , Rabbits , Tetradecanoylphorbol Acetate/pharmacology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...